Pfizer Shares Waver After Seagen’s Mixed Top‑Line Data on Origin Cancer Therapy
Pfizer Shares Slip After Seagen’s Origin Cancer Drug Delivers Mixed Top‑line Results
Jazz Pharma’s Promising Lung‑Cancer Candidate Stumbles in Late‑Stage Study
Eli Lilly's Cancer Revolution: How Loxo Oncology Reshaped an Empire
Zentalis Pharmaceuticals to Unveil Promising Cancer Therapy Updates at AACR 2026
CureVac's Crossroads: Why Wall Street Is Treading Carefully Towards 2026
A Fresh Look at Regeneron: Why Analysts Are Seeing Significant Upside
Beyond the Pandemic: Moderna's Ambitious Bet on mRNA as the Next Big Cancer Weapon